Merck has unveiled plans to invest more than $650 million and create more than 400 jobs in North Carolina, building a new production facility at its Maurice R. Hilleman Center for Vaccine Manufacturing in Durham and expanding its packaging operations in Wilson. This substantial project will enable Merck to meet growing demand for Gardasil and Gardasil 9 recombinant human papillomavirus (HPV) vaccine, which is used to prevent several cancers associated with HPV.
 
“The life science industry cluster in North Carolina enjoys a well-earned reputation as one of the nation’s leading centers for biotech innovation,” said Anthony M. Copeland, North Carolina Commerce Secretary. “Merck’s long experience in our state gave them the confidence to bring this important new operation to North Carolina.”
 
Merck’s Gardasil 9 vaccine helps prevent nine strains of HPV, including two HPV types that cause an estimated 70% of cervical cancers. Merck’s project to expand its North Carolina facilities includes plans to design, build, and win qualification from the FDA for a new 225,000 square foot manufacturing facility to produce active ingredient for the vaccine. The new facility will be located at Merck’s current manufacturing center in Durham.
 
“Merck is delighted to bring additional investment and jobs to North Carolina,” said Sanat Chattopadhyay, executive vice president, Merck, and president, Merck manufacturing division. “Our Durham and Wilson plants are key strategic sites in the Merck global manufacturing network. And the strong support of the state is critical for the success of businesses such as ours.”